Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- cardiovascular -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (19)	1/27/2002 11:48:38 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 214

OT <<More BTW, avan will have results in anti-C1 (but actually inhibit at c3 I hear) in cpb soon. Should be very interesting from efficacy point of view, though I am most interested in its safety results.>> I think that safety will be OK (from infant trials), but will be surprised if efficacy are at great significance. Novartis would grab cpb indication long time ago if they think that it is worth risk. In this case I will prefer to be surprised than need to report new failure. <g> Miljenko